Mizuho Markets Americas LLC Sells 93,110 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Key Points

• Mizuho Markets Americas LLC reduced its holdings in Halozyme Therapeutics by 19.9%, selling 93,110 shares and owning approximately 0.30% of the company post-sale, valuing its stake at $23.88 million.
• Halozyme Therapeutics reported $1.54 earnings per share for the quarter, exceeding estimates, with revenue of $325.72 million, a 40.8% increase from the previous year.
• The stock currently has a consensus rating of "Hold" with varying opinions from analysts, reflecting moderate confidence in the company's performance and future outlook.

Mizuho Markets Americas LLC cut its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 19.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 374,173 shares of the biopharmaceutical company's stock after selling 93,110 shares during the quarter. Mizuho Markets Americas LLC owned about 0.30% of Halozyme Therapeutics worth $23,876,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Capital World Investors acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth approximately $35,773,000. D. E. Shaw & Co. Inc. increased its position in shares of Halozyme Therapeutics by 171.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock worth $39,750,000 after purchasing an additional 524,802 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at about $21,838,000. LSV Asset Management increased its holdings in Halozyme Therapeutics by 41.9% in the first quarter. LSV Asset Management now owns 895,191 shares of the biopharmaceutical company's stock valued at $57,122,000 after buying an additional 264,130 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec increased its holdings in Halozyme Therapeutics by 280.4% in the fourth quarter. Caisse DE Depot ET Placement DU Quebec now owns 357,579 shares of the biopharmaceutical company's stock valued at $17,096,000 after buying an additional 263,570 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on HALO. HC Wainwright boosted their price target on shares of Halozyme Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. Morgan Stanley raised Halozyme Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $62.00 to $75.00 in a report on Wednesday, August 6th. Leerink Partners lowered Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a research note on Tuesday, May 13th. The Goldman Sachs Group began coverage on Halozyme Therapeutics in a research note on Thursday, July 10th. They issued a "neutral" rating and a $55.00 price objective on the stock. Finally, Wells Fargo & Company upped their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $66.56.

Halozyme Therapeutics Stock Up 0.9%

HALO traded up $0.60 during trading hours on Thursday, hitting $65.73. 841,277 shares of the company's stock were exchanged, compared to its average volume of 1,954,366. The stock has a market cap of $8.10 billion, a price-to-earnings ratio of 15.06, a PEG ratio of 0.35 and a beta of 1.17. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $70.50. The stock's 50-day moving average is $56.56 and its two-hundred day moving average is $58.10. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating analysts' consensus estimates of $1.23 by $0.31. The company had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company's quarterly revenue was up 40.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.91 EPS. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the sale, the chief executive officer owned 733,719 shares of the company's stock, valued at $46,598,493.69. This trade represents a 2.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold 80,000 shares of company stock worth $4,532,600 in the last 90 days. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.